MRK
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
- —
- Total sold
- —
- Last activity
- —
- Last synced
-
2026-09-13 10:23:38
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
No AI score has reached this site for this company yet, so there's no signal to show - and that's the same for every tier, paid or not. Scores arrive with the scheduled sync from the research pipeline; once one lands, the strength of the signal appears here.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 72.0% | 76.3% | 73.2% | 70.6% | 72.0% | |
| Ebit Margin | 34.5% | 33.0% | 5.0% | 29.4% | 30.2% | |
| Ebitda Margin | 43.5% | 40.1% | 11.5% | 36.0% | 36.8% | |
| Operating Profit Margin | 36.2% | 31.5% | 4.9% | 30.8% | 27.1% | |
| Pretax Profit Margin | 32.4% | 31.1% | 3.1% | 27.7% | 28.5% | |
| Continuous Operations Profit Margin | 28.1% | 26.7% | 0.6% | 24.5% | 25.4% | |
| Net Profit Margin | 28.1% | 26.7% | 0.6% | 24.5% | 26.8% | |
| Bottom Line Profit Margin | 28.1% | 26.7% | 0.6% | 24.5% | 26.8% | |
| Current Ratio | 1.536 | 1.365 | 1.252 | 1.474 | 1.268 | |
| Quick Ratio | 1.301 | 1.150 | 1.005 | 1.230 | 1.018 | |
| Solvency Ratio | 0.286 | 0.306 | 0.061 | 0.292 | 0.241 | |
| Cash Ratio | 0.514 | 0.466 | 0.266 | 0.524 | 0.339 | |
| Price To Earnings Ratio | 14.419 | 14.716 | 778.714 | 19.363 | 14.853 | |
| Price To Earnings Growth Ratio | 1.805 | 0.003 | -7.982 | 1.753 | 0.175 | |
| Forward Price To Earnings Growth Ratio | 1.805 | 0.003 | -7.982 | 1.753 | 0.175 | |
| Price To Earnings Diluted Ratio | 14.459 | 14.760 | 778.714 | 19.431 | 14.911 | |
| Price To Earnings Diluted Growth Ratio | 1.805 | 0.003 | -7.983 | 1.752 | 0.176 | |
| Price To Book Ratio | 5.006 | 5.439 | 7.389 | 6.108 | 5.078 | |
| Price To Sales Ratio | 4.056 | 3.925 | 4.619 | 4.739 | 3.981 | |
| Price To Free Cash Flow Ratio | 21.307 | 13.919 | 30.370 | 19.101 | 20.070 | |
| Price To Operating Cash Flow Ratio | 15.988 | 11.733 | 21.350 | 14.712 | 13.743 | |
| Debt To Assets Ratio | 0.369 | 0.327 | 0.340 | 0.293 | 0.328 | |
| Debt To Equity Ratio | 0.961 | 0.826 | 0.965 | 0.695 | 0.907 | |
| Debt To Capital Ratio | 0.490 | 0.452 | 0.491 | 0.410 | 0.476 | |
| Long Term Debt To Capital Ratio | 0.471 | 0.427 | 0.473 | 0.385 | 0.446 | |
| Financial Leverage Ratio | 2.602 | 2.529 | 2.839 | 2.374 | 2.768 | |
| Working Capital Turnover Ratio | 5.082 | 7.623 | 6.695 | 6.632 | 14.260 | |
| Operating Cash Flow Ratio | 0.581 | 0.755 | 0.506 | 0.788 | 0.591 | |
| Operating Cash Flow Sales Ratio | 0.254 | 0.335 | 0.216 | 0.322 | 0.290 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.750 | 0.843 | 0.703 | 0.770 | 0.685 | |
| Debt Service Coverage Ratio | 6.004 | 5.843 | 2.143 | 6.670 | 5.089 | |
| Interest Coverage Ratio | 17.307 | 15.910 | 2.578 | 19.004 | 16.376 | |
| Short Term Operating Cash Flow Coverage Ratio | 5.713 | 8.104 | 9.480 | 9.812 | 5.850 | |
| Operating Cash Flow Coverage Ratio | 0.326 | 0.561 | 0.359 | 0.597 | 0.407 | |
| Capital Expenditure Coverage Ratio | 4.006 | 6.367 | 3.367 | 4.352 | 3.172 | |
| Dividend Paid And Capex Coverage Ratio | 1.340 | 1.915 | 1.150 | 1.675 | 1.276 | |
| Dividend Payout Ratio | 0.448 | 0.458 | 20.397 | 0.483 | 0.507 | |
| Enterprise Value Multiple | 10.591 | 10.772 | 44.462 | 14.085 | 12.315 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 72.0% | ▼-4.3% | ▼-0.9% |
| Ebit Margin | 34.5% | ▲1.5% | ▲8.1% |
| Ebitda Margin | 43.5% | ▲3.5% | ▲10.0% |
| Operating Profit Margin | 36.2% | ▲4.7% | ▲10.1% |
| Pretax Profit Margin | 32.5% | ▲1.4% | ▲7.9% |
| Continuous Operations Profit Margin | 28.1% | ▲1.4% | ▲7.1% |
| Net Profit Margin | 28.1% | ▲1.4% | ▲6.8% |
| Bottom Line Profit Margin | 28.1% | ▲1.4% | ▲6.8% |
| Current Ratio | 1.536 | ▲0.172 | ▲0.157 |
| Quick Ratio | 1.301 | ▲0.151 | ▲0.160 |
| Solvency Ratio | 0.286 | ▼-0.019 | ▲0.049 |
| Cash Ratio | 0.514 | ▲0.048 | ▲0.092 |
| Price To Earnings Ratio | 14.419 | ▼-0.297 | ▼-153.994 |
| Price To Earnings Growth Ratio | 1.805 | ▲1.802 | ▲2.654 |
| Forward Price To Earnings Growth Ratio | 1.805 | ▲1.802 | ▲2.654 |
| Price To Earnings Diluted Ratio | 14.459 | ▼-0.301 | ▼-153.996 |
| Price To Earnings Diluted Growth Ratio | 1.805 | ▲1.802 | ▲2.654 |
| Price To Book Ratio | 5.006 | ▼-0.432 | ▼-0.798 |
| Price To Sales Ratio | 4.056 | ▲0.131 | ▼-0.208 |
| Price To Free Cash Flow Ratio | 21.308 | ▲7.388 | ▲0.354 |
| Price To Operating Cash Flow Ratio | 15.988 | ▲4.255 | ▲0.483 |
| Debt To Assets Ratio | 0.369 | ▲0.042 | ▲0.038 |
| Debt To Equity Ratio | 0.961 | ▲0.134 | ▲0.090 |
| Debt To Capital Ratio | 0.490 | ▲0.037 | ▲0.026 |
| Long Term Debt To Capital Ratio | 0.470 | ▲0.044 | ▲0.030 |
| Financial Leverage Ratio | 2.602 | ▲0.073 | ▼-0.020 |
| Working Capital Turnover Ratio | 5.082 | ▼-2.541 | ▼-2.976 |
| Operating Cash Flow Ratio | 0.582 | ▼-0.174 | ▼-0.063 |
| Operating Cash Flow Sales Ratio | 0.254 | ▼-0.081 | ▼-0.030 |
| Free Cash Flow Operating Cash Flow Ratio | 0.750 | ▼-0.093 | ▲0.000 |
| Debt Service Coverage Ratio | 6.004 | ▲0.162 | ▲0.854 |
| Interest Coverage Ratio | 17.307 | ▲1.398 | ▲3.072 |
| Short Term Operating Cash Flow Coverage Ratio | 5.713 | ▼-2.391 | ▼-2.078 |
| Operating Cash Flow Coverage Ratio | 0.326 | ▼-0.235 | ▼-0.124 |
| Capital Expenditure Coverage Ratio | 4.006 | ▼-2.361 | ▼-0.247 |
| Dividend Paid And Capex Coverage Ratio | 1.341 | ▼-0.574 | ▼-0.131 |
| Dividend Payout Ratio | 0.448 | ▼-0.010 | ▼-4.011 |
| Enterprise Value Multiple | 10.591 | ▼-0.181 | ▼-7.854 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $263.36B | $251.88B | $277.67B | $280.93B | $193.90B | |
| Enterprise value | $299.33B | $276.91B | $307.10B | $300.22B | $220.43B | |
| EV / Sales | 4.61x | 4.32x | 5.11x | 5.06x | 4.53x | |
| EV / Op. cash flow | 18.17x | 12.90x | 23.61x | 15.72x | 15.62x | |
| EV / Free cash flow | 24.22x | 15.30x | 33.59x | 20.41x | 22.82x | |
| EV / EBITDA | 10.59x | 10.77x | 44.46x | 14.09x | 12.31x | |
| Net debt / EBITDA | 1.27x | 0.97x | 4.26x | 0.91x | 1.48x | |
| Current ratio | 1.54x | 1.36x | 1.25x | 1.47x | 1.27x | |
| Income quality | 0.90x | 1.25x | 35.63x | 1.31x | 1.14x | |
| Graham number | $59 | $53 | $7 | $48 | $42 | |
| Graham net-net | -$23 | -$18 | -$20 | -$16 | -$20 | |
| Tax burden | 86.6% | 85.9% | 19.3% | 88.3% | 94.0% | |
| Interest burden | 93.9% | 94.0% | 62.2% | 94.5% | 94.5% | |
| Working capital | $15.19B | $10.36B | $6.47B | $11.48B | $6.39B | |
| Invested capital | $90.27B | $72.18B | $68.73B | $74.38B | $69.87B | |
| Return on assets | 13.3% | 14.6% | 0.3% | 13.3% | 12.3% | |
| Operating ROA | 18.5% | 18.1% | 2.7% | 17.0% | 13.4% | |
| Return on tangible assets | 20.6% | 21.6% | 0.5% | 21.5% | 21.2% | |
| Return on equity | 34.7% | 37.0% | 1.0% | 31.6% | 34.2% | |
| Return on invested capital | 18.3% | 19.0% | 0.7% | 18.5% | 13.9% | |
| Return on capital employed | 21.6% | 22.8% | 3.6% | 21.5% | 16.1% | |
| Earnings yield | 6.9% | 6.8% | 0.1% | 5.2% | 6.7% | |
| Free cash flow yield | 4.7% | 7.2% | 3.3% | 5.2% | 5.0% | |
| Capex / Op. cash flow | 25.0% | 15.7% | 29.7% | 23.0% | 31.5% | |
| Capex / Depreciation | 70.4% | 74.9% | 99.8% | 112.3% | 138.4% | |
| Capex / Sales | 6.3% | 5.3% | 6.4% | 7.4% | 9.1% | |
| SG&A / Sales | 16.5% | 15.7% | 16.4% | 16.3% | 19.3% | |
| R&D / Sales | 19.3% | 28.0% | 50.8% | 22.9% | 25.1% | |
| Stock comp / Sales | 0.0% | 1.2% | 1.1% | 0.9% | 1.0% | |
| Intangibles / Total assets | 35.3% | 32.5% | 36.8% | 38.0% | 41.8% | |
| Days sales outstanding | 71d | 58d | 63d | 58d | 69d | |
| Days payables outstanding | 88d | 98d | 89d | 89d | 123d | |
| Operating cycle | 205d | 205d | 207d | 182d | 229d | |
| Cash conversion cycle | 116d | 107d | 118d | 93d | 105d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+4.6%EV / Sales ▲+6.8%EV / EBITDA ▼-1.7%EV / Op. cash flow ▲+5.273Earnings yield ▲+0.001Graham number ▲+6.003
Profitability
Return on equity ▼-0.023Return on assets ▼-0.013Return on invested capital ▼-0.007Return on capital employed ▼-0.012Operating ROA ▲+0.004Income quality ▼-0.351Tax burden ▲+0.008
Efficiency
Days sales outstanding ▲+12.815Days payables outstanding ▼-9.649Operating cycle ▼-0.386Cash conversion cycle ▲+9.262Capex / Sales ▲+0.011R&D / Sales ▼-0.087
Balance-sheet strength
Current ratio ▲+0.172Net debt / EBITDA ▲+0.299Working capital ▲+4827000000.000Invested capital ▲+18093000000.000Intangibles / Total assets ▲+0.028
Change over 5 years
Valuation
Market cap ▲+35.8%EV / Sales ▲+1.9%EV / EBITDA ▼-14.0%EV / Op. cash flow ▲+2.548Earnings yield ▲+0.002Graham number ▲+16.899
Profitability
Return on equity ▲+0.005Return on assets ▲+0.010Return on invested capital ▲+0.044Return on capital employed ▲+0.055Operating ROA ▲+0.051Income quality ▼-0.239Tax burden ▼-0.074
Efficiency
Days sales outstanding ▲+2.107Days payables outstanding ▼-35.115Operating cycle ▼-23.794Cash conversion cycle ▲+11.321Capex / Sales ▼-0.028R&D / Sales ▼-0.059
Balance-sheet strength
Current ratio ▲+0.268Net debt / EBITDA ▼-0.210Working capital ▲+8795000000.000Invested capital ▲+20402000000.000Intangibles / Total assets ▼-0.066
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-08-19 | Maria Elvira Salazar | Purchase | $15,001 - $50,000 |
| 2026-08-19 | Maria Elvira Salazar | Purchase | $15,001 - $50,000 |
| 2026-08-19 | Maria Elvira Salazar | Purchase | $15,001 - $50,000 |
| 2026-08-07 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2026-02-03 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2026-01-13 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2025-12-18 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-12-17 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-11-17 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-12 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-22 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-08-27 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-08-13 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-04 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-03 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-07-10 | Ritchie Torres | Sale (Full) | $1,001 - $15,000 |
| 2025-06-23 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-15 | Scott Franklin | Sale (Full) | $1,001 - $15,000 |
| 2025-06-12 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2025-05-30 | Gilbert Ray Cisneros | Sale | $1,001 - $15,000 |
| 2025-05-30 | Gilbert Ray Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2025-05-19 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2025-05-14 | Robert P. Bresnahan | Sale (Full) | $15,001 - $50,000 |
| 2025-05-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-05-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-05-04 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-04-28 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-04-20 | Bruce Westerman | Sale (Full) | $1,001 - $15,000 |
| 2025-04-16 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-04-08 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-04-07 | Robert P. Bresnahan | Purchase | $15,001 - $50,000 |
| 2025-04-02 | Michael T. McCaul | Purchase | $100,001 - $250,000 |
| 2025-03-30 | Gilbert Ray Cisneros | Sale (Partial) | $15,001 - $50,000 |
| 2025-03-19 | Kelly Morrison | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-18 | Sheri Biggs | Sale (Full) | $15,001 - $50,000 |
| 2025-03-02 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2025-02-25 | Gilbert Ray Cisneros | Purchase | $15,001 - $50,000 |
| 2025-02-24 | Robert P. Bresnahan | Sale (Full) | $15,001 - $50,000 |
| 2025-02-23 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-01-26 | Josh S. Gottheimer | Sale (Full) | $15,001 - $50,000 |
| 2025-01-23 | Gilbert Ray Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2025-01-16 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2025-01-15 | Byron Donalds | Sale (Full) | $1,001 - $15,000 |
| 2025-01-15 | Byron Donalds | Sale (Full) | $1,001 - $15,000 |
| 2025-01-14 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2025-01-14 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2025-01-10 | Keith Self | Sale | $1,001 - $15,000 |
| 2025-01-10 | Keith Self | Sale | $1,001 - $15,000 |
| 2024-11-07 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-10-28 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-10-09 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2024-10-09 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2024-09-25 | Ritchie Torres | Purchase | $1,001 - $15,000 |
| 2024-09-23 | Jonathan Jackson | Sale (Full) | $15,001 - $50,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-03 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-08-06 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2024-08-01 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2024-07-01 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2024-06-20 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-04-09 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2024-02-23 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-02-20 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2024-02-20 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2024-01-23 | Kathy E. Manning | Purchase | $15,001 - $50,000 |
| 2024-01-23 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-12-27 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-11-09 | John James | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-23 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-25 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-12 | Michael C. Burgess | Sale (Full) | $1,001 - $15,000 |
| 2023-09-10 | Scott Franklin | Sale (Partial) | $15,001 - $50,000 |
| 2023-09-07 | Lois Frankel | Sale (Full) | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-05 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-08-31 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-01 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-07-13 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-07-13 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2023-07-11 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-06-27 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-06-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-12 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-05-12 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2021-03-10 | Rick W. Allen | Sale (Full) | $15,001 - $50,000 |
| 2020-07-02 | Rick W. Allen | Purchase | $15,001 - $50,000 |
| 2017-11-30 | Rick W. Allen | Sale (Full) | $1,001 - $15,000 |
Recent news
- 2026-09-12 REVOLUTIONIZING HEALTHCARE: Tempus partners with Merck on AI-driven precision medicine Tempus CEO Eric Lefkofsky discusses the company''s artificial intelligence-driven precision medicine partnership with Merck on ‘The Claman Countdown.'' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #tempus #ericlefkofsky #lefkofsky #merck #ai #artificialintelligence #healthcare #precisionmedicine #medicine #medicalresearch #technology #clinicaldata #patientcare #healthtech
- 2026-09-12 2 Outstanding Dividend Stocks to Buy and Hold for 10 Years Income seekers can''t go wrong with these companies.
- 2026-09-11 MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE Merck is expanding its pipeline and newer drug portfolio to offset Keytruda''s 2028 LOE and drive long-term growth.
- 2026-09-10 Congresswoman Bets on Elon Musk, Warren Buffett: Here''s the Latest Stock Transactions Retail investors often monitor the trading activity of members of Congress. Investors may want to pay particular attention to recent trades from one member, with stocks connected to Elon Musk and Warren Buffett among the bets.
- 2026-09-10 Merck (MRK) Dips More Than Broader Market: What You Should Know In the most recent trading session, Merck (MRK) closed at $144.71, indicating a -1.91% shift from the previous trading day.
- 2026-09-10 Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 2026-09-10 Merck Targets $70B Pipeline as It Prepares for KEYTRUDA Exclusivity Loss Merck & Co., Inc. NYSE: MRK executives outlined a strategy centered on pipeline investment, new product launches and targeted business development as the company prepares for the eventual loss of exclusivity for KEYTRUDA.
- 2026-09-10 Archford Capital Strategies LLC Has $3.52 Million Position in Merck & Co., Inc. $MRK Archford Capital Strategies LLC lessened its stake in Merck and Co., Inc. (NYSE: MRK) by 20.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,354 shares of the company''s stock after selling 6,991 shares during the period. Archford Capital Strategies
- 2026-09-09 Merck & Co., Inc. (MRK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Merck & Co., Inc. (MRK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
- 2026-09-09 The Big 3: ROST, MRK, AAPL Don Kaufman (@Theotrade) calls the U.S. Treasury''s $6 billion bond buyback plan "nominal" to investors seeking relief as the inflation picture gets wider by the day. However, he sees bearish opportunities in Wednesday''s Big 3 by outlining example options trades in Ross Stores (ROST), Merck (MRK), and Apple (AAPL).